Jinarc (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jinarc (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD). (Source: Drug Development Technology)
Source: Drug Development Technology - March 19, 2015 Category: Pharmaceuticals Source Type: news
CHMP Backs Tolvaptan (Jinarc) for Rare Kidney DiseaseCHMP Backs Tolvaptan (Jinarc) for Rare Kidney Disease
Tolvaptan, a vasopressin-2-receptor antagonist that slows cyst formation, would be the first drug specifically approved in the European Union for autosomal dominant polycystic kidney disease. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news
Expert panel recommends new approaches to management of ADPKD
A report has been published by the European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, as well as patient group representatives, dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD) – a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 30, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Practical therapeutics Nephrology Patient care Autosomal dominant polycystic kidney disease cysts EAF economic impact hypertension Latest News Source Type: news
No Help From Dual RAAS Blockade in PKD (CME/CE)
(MedPage Today) -- No benefit to combining ACE inhibitor with ARB in polycystic kidney disease. (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 17, 2014 Category: Urology & Nephrology Source Type: news
Dual RAAS Blockade No Better Than ACE Inhibitor to Slow PKDDual RAAS Blockade No Better Than ACE Inhibitor to Slow PKD
In early or moderate autosomal dominant polycystic kidney disease, dual RAAS blockade did not slow the long-term decline in kidney function when compared with an ACE inhibitor alone. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2014 Category: Consumer Health News Tags: Nephrology News Source Type: news
Two drugs are no more effective than 1 to treat common kidney disease
(NIH/National Institute of Diabetes and Digestive and Kidney Diseases) Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 15, 2014 Category: Global & Universal Source Type: news
Kadmon begins Phase IIa Portion of KD020 study
Kadmon has started the Phase IIa portion of a Phase Ib/IIa study of KD020 in autosomal dominant polycystic kidney disease (ADPKD), following unanimous recommendation of the study's data safety committee. (Source: Drug Development Technology)
Source: Drug Development Technology - June 22, 2014 Category: Pharmaceuticals Source Type: news
European ADPKD forum launches
The European ADPKD Forum (EAF) has been created, which is a new multidisciplinary group of leading medical and patient group experts dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 2, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Nephrology Autosomal dominant polycystic kidney disease genetic kidney disease Latest News multidisciplinary expert group Source Type: news
Patients with a certain form of kidney disease may have reduced risk of cancer
After adjusting for demographic differences between kidney transplant recipients with polycystic kidney disease (PKD) and other kidney transplant recipients, PKD patients were 16 percent less likely to develop cancer than others who received a kidney transplant. Polycystic kidney disease (PKD) is a kidney disorder passed down through families in which many cysts form in the kidneys, causing them to become enlarged. It's thought to have cancer-like features, but cancer risk has never been compared between PKD patients and others with kidney disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 22, 2014 Category: Science Source Type: news
Type of Kidney Disease May Dictate Cancer Risk
Study of transplant recipients finds prospects best with polycystic kidney disease
Source: HealthDay
Related MedlinePlus Pages: Cancer, Kidney Cysts, Kidney Transplantation (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 22, 2014 Category: Consumer Health News Source Type: news
Type of Kidney Disease May Dictate Cancer Risk
Study of transplant recipients finds prospects best with polycystic kidney disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 22, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Nephrology, Oncology, Organ Transplants, News, Source Type: news
Statins given early decrease progression of kidney disease
(University of Colorado Denver) Results from a study by University of Colorado School of Medicine researchers show that pravastatin, a medicine widely used for treatment of high cholesterol, also slows down the growth of kidney cysts in children and young adults with autosomal dominant polycystic kidney disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2014 Category: Biology Source Type: news
Otsuka's kidney drug Samsca receives approval in Japan
Otsuka Pharmaceutical has received regulatory approval from Japanese authorities for Samsca for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 26, 2014 Category: Pharmaceuticals Source Type: news
Polycystic Kidney Disease (PKD)
Title: Polycystic Kidney Disease (PKD)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/19/2014 12:00:00 AM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - March 19, 2014 Category: Gastroenterology Source Type: news
Could grapefruit be good for your kidneys?
Scientists at Royal Holloway, University of London, have discovered that a natural product found in grapefruit can prevent kidney cysts from forming.Naringenin, which is also present in other citrus fruits, has been found to successfully block the formation of kidney cysts, an effect that occurs in polycystic kidney disease, by regulating the PKD2 protein responsible for the condition. With few treatments currently available, symptoms include high blood pressure and loss of kidney function, and lead to the need for dialysis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2014 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
